Cullinan Therapeutics (CGEM) News Today $8.56 +0.70 (+8.91%) Closing price 04:00 PM EasternExtended Trading$8.62 +0.06 (+0.70%) As of 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CGEM Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Cullinan Therapeutics: Worthy Of A Small PositionOctober 17 at 7:01 AM | seekingalpha.comCullinan Therapeutics, Inc. (NASDAQ:CGEM) Given Consensus Rating of "Moderate Buy" by AnalystsOctober 17 at 2:38 AM | americanbankingnews.comCullinan Therapeutics, Inc. (NASDAQ:CGEM) Given Consensus Recommendation of "Moderate Buy" by BrokeragesOctober 17 at 2:38 AM | marketbeat.comCullinan Therapeutics (NASDAQ:CGEM) Stock Price Up 11.4% - Here's What HappenedOctober 16, 2025 | marketbeat.comCullinan Therapeutics (NASDAQ:CGEM) Trading Up 11.5% - Here's WhyOctober 16, 2025 | marketbeat.comCullinan Management (CGEM) Gets a Buy from Clear StreetOctober 15, 2025 | theglobeandmail.comTaiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib in Patients with NSCLC with EGFR mutations and Active Brain Metastases at the ESMO Congress 2025October 12, 2025 | prnewswire.comLynx1 Capital Management Lp Buys 277,298 Shares of Cullinan Therapeutics (NASDAQ:CGEM) StockOctober 11, 2025 | marketbeat.comCullinan Therapeutics (NASDAQ:CGEM) Major Shareholder Buys $3,593,698.00 in StockOctober 11, 2025 | marketbeat.comCullinan Therapeutics (NASDAQ:CGEM) Major Shareholder Lynx1 Capital Management Lp Purchases 626,043 SharesOctober 11, 2025 | marketbeat.comCullinan Therapeutics (NASDAQ:CGEM) Major Shareholder Acquires $2,040,913.28 in StockOctober 11, 2025 | insidertrades.comLynx1 capital buys Cullinan Therapeutics (CGEM) shares worth $9.8mOctober 10, 2025 | investing.comCullinan Therapeutics (NASDAQ:CGEM) Receives Sell (E+) Rating from Weiss RatingsOctober 9, 2025 | marketbeat.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Novan (NOVN) and Cullinan Management (CGEM)September 26, 2025 | theglobeandmail.comCullinan Therapeutics, Inc. (NASDAQ:CGEM) Given Average Rating of "Moderate Buy" by AnalystsSeptember 22, 2025 | marketbeat.comCullinan Therapeutics (NASDAQ:CGEM) Upgraded to "Hold" at Zacks ResearchSeptember 19, 2025 | marketbeat.comCullinan Therapeutics (NASDAQ:CGEM) Given "Buy" Rating at HC WainwrightSeptember 14, 2025 | marketbeat.comBTIG Research Reiterates Buy Rating for Cullinan Therapeutics (NASDAQ:CGEM)September 13, 2025 | marketbeat.comCullinan Therapeutics to Participate in Fireside Chat at the Stifel 2025 Virtual Immunology and Inflammation ForumSeptember 12, 2025 | globenewswire.comCullinan Therapeutics, Inc. (CGEM) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 10, 2025 | seekingalpha.comTrexquant Investment LP Invests $518,000 in Cullinan Therapeutics, Inc. $CGEMSeptember 10, 2025 | marketbeat.comTaiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib at the IASLC 2025 World Conference on Lung CancerSeptember 9, 2025 | prnewswire.comWalleye Capital LLC Decreases Stake in Cullinan Therapeutics, Inc. $CGEMSeptember 8, 2025 | marketbeat.comRafferty Asset Management LLC Sells 34,716 Shares of Cullinan Therapeutics, Inc. $CGEMSeptember 5, 2025 | marketbeat.comBraidwell LP Reduces Position in Cullinan Therapeutics, Inc. $CGEMSeptember 3, 2025 | marketbeat.com188,030 Shares in Cullinan Therapeutics, Inc. $CGEM Bought by Nuveen LLCSeptember 2, 2025 | marketbeat.comCullinan Therapeutics, Inc. $CGEM Holdings Raised by Vanguard Group Inc.August 31, 2025 | marketbeat.comCullinan Therapeutics, Inc. (NASDAQ:CGEM) Given Average Rating of "Buy" by AnalystsAugust 30, 2025 | marketbeat.comBrokers Set Expectations for CGEM Q3 EarningsAugust 26, 2025 | marketbeat.comResearch Analysts Offer Predictions for CGEM Q1 EarningsAugust 24, 2025 | marketbeat.comCullinan Therapeutics, Inc. $CGEM Shares Acquired by Algert Global LLCAugust 24, 2025 | marketbeat.comHC Wainwright Reiterates Buy Rating for Cullinan Therapeutics (NASDAQ:CGEM)August 23, 2025 | marketbeat.comCullinan Therapeutics to Participate in Upcoming Investor ConferencesAugust 21, 2025 | globenewswire.comCullinan Therapeutics assumed with a Buy at H.C. WainwrightAugust 21, 2025 | msn.comVoss Capital LP Acquires 52,639 Shares of Cullinan Therapeutics, Inc. $CGEMAugust 21, 2025 | marketbeat.comMorgan Stanley Has Lowered Expectations for Cullinan Therapeutics (NASDAQ:CGEM) Stock PriceAugust 20, 2025 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Raises Stock Holdings in Cullinan Therapeutics, Inc. $CGEMAugust 20, 2025 | marketbeat.comWilliam Blair Has Pessimistic Outlook of CGEM Q3 EarningsAugust 11, 2025 | marketbeat.comCullinan Therapeutics: Q2 Earnings SnapshotAugust 7, 2025 | finance.yahoo.comCullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial ResultsAugust 7, 2025 | globenewswire.comCullinan Therapeutics (CGEM) to Release Earnings on ThursdayAugust 7, 2025 | marketbeat.comCullinan Therapeutics, Inc. (NASDAQ:CGEM) Given Consensus Rating of "Buy" by BrokeragesAugust 3, 2025 | marketbeat.comCullinan Therapeutics to Present Updated Zipalertinib Data at IASLC 2025 World Conference on Lung CancerAugust 1, 2025 | msn.comCullinan Therapeutics: Betting On Zipalertinib NDA CatalystJuly 15, 2025 | seekingalpha.comWe're Keeping An Eye On Cullinan Therapeutics' (NASDAQ:CGEM) Cash Burn RateJuly 10, 2025 | finance.yahoo.comCullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Consensus Recommendation of "Buy" from BrokeragesJuly 9, 2025 | marketbeat.comCGEM - Cullinan Therapeutics Inc Dividends - MorningstarJuly 2, 2025 | morningstar.comMAssenagon Asset Management S.A. Cuts Stock Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM)June 21, 2025 | marketbeat.comCullinan Therapeutics, Inc. (NASDAQ:CGEM) Given Average Rating of "Buy" by BrokeragesJune 14, 2025 | marketbeat.comCullinan Therapeutics (NASDAQ:CGEM) Coverage Initiated at Stifel NicolausJune 11, 2025 | marketbeat.com Get Cullinan Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CGEM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CGEM Media Mentions By Week CGEM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CGEM News Sentiment▼0.500.49▲Average Medical News Sentiment CGEM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CGEM Articles This Week▼64▲CGEM Articles Average Week Get the Latest News and Ratings for CGEM and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Cullinan Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies GPCR News BHVN News STOK News ABCL News IMCR News VCEL News JANX News EWTX News RCUS News HRMY News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CGEM) was last updated on 10/20/2025 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in JanuaryCurious about crypto but still stuck scrolling endless threads? People who get in early aren’t just lucky—they...Crypto 101 Media | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredElon Musk is on the lineElon Musk says November 6 could "affect the future of the world" Get ready for the biggest pivot in corpora...Altimetry | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredWhat Wall Street Won’t Say Out LoudDiscover the 7 key indicators before everyone else doesAmerican Alternative | SponsoredMelt-up warning Porter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cullinan Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cullinan Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
